Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Anti-Human ATTR/Transthyretin amyloidosis Antibody (NI-006)

Catalog #:   DHC01302 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC01302

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Transthyretin, Prealbumin, TBPA, TTR, PALB, ATTR

Concentration

1.86 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P02766

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

NI-006, NI 006, NI006

Clone ID

NI-006

Data Image
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Current and emerging treatment options for transthyretin amyloid cardiomyopathy., PMID:40425273

Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy., PMID:40335224

Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions., PMID:40232627

Concurrent Therapy for Immunoglobulin Light Chain Cardiac Amyloidosis and Transthyretin Cardiac Amyloidosis: A Case Report., PMID:39924245

Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies., PMID:39841315

New therapies to treat cardiac amyloidosis., PMID:39819772

Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation., PMID:39775625

Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications., PMID:39714070

Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis., PMID:39627935

Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022., PMID:39592278

Optimizing drug therapies in cardiac amyloidosis., PMID:39586360

Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances., PMID:39551565

PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study., PMID:39472768

Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling., PMID:39410666

Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis., PMID:39338387

[Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report]., PMID:39106513

Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis., PMID:39086890

Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients., PMID:39029855

Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis., PMID:38844305

Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment., PMID:38809394

Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis., PMID:38801321

Treatment of transthyretin cardiac amyloidosis., PMID:38652263

Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer., PMID:38359019

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy., PMID:38233673

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy., PMID:38184468

Epidemiological study of the subtype frequency of systemic amyloidosis listed in the Annual of the Pathological Autopsy Cases in Japan., PMID:38088470

Pathomorphological Features of the Novel Coronavirus Disease in Patients with Systemic Amyloidosis., PMID:37893183

Randall-Type Monoclonal Immunoglobulin Deposition Disease in Bone Scintigraphy., PMID:37883135

Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion., PMID:37854603

Coronary artery bypass grafting for triple vessel disease in cardiac amyloidosis., PMID:37699742

Strong positive light chain immunostaining in a patient with transthyretin amyloidosis., PMID:37551718

RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease., PMID:37470509

Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures., PMID:37439769

Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy., PMID:37285532

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid., PMID:37212440

Treatment of amyloidosis: present and future., PMID:37091663

Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis., PMID:36795075

Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria., PMID:36621346

Current approaches to the diagnosis and management of amyloidosis., PMID:36478370

Dual Targeting of Soluble Oligomeric and Aggregated Transthyretin with a Monoclonal Antibody Ameliorates Experimental Neuropathy., PMID:36290413

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges., PMID:35456241

Cardiac Amyloidosis Treatment., PMID:35414852

Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist., PMID:35325395

Cardiac microcalcifications in transthyretin (ATTR) amyloidosis., PMID:35077727

Developing Therapy for Transthyretin Amyloidosis., PMID:35077703

Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease., PMID:34814699

Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution., PMID:34653913

[Heart damage in the combined types of systemic amyloidosis]., PMID:34609800

Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment., PMID:34443678

Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissue., PMID:34428239

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Anti-Human ATTR/Transthyretin amyloidosis Antibody (NI-006) [DHC01302]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only